Incyte (INCY) Profit After Tax Growth (1y) (2011 - 2026)
Powered by 
Analysis
Incyte (INCY) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.31 Bn | 130.45 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.17 Bn | 77.17 Bn | 3.93 Bn | -8.35% |
| 3 | Argenx Se | 63.25 Bn | 58.07 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.27 Bn | 53.13 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 40.01 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.26 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -12.04% |
| 9 | Insmed | 27.37 Bn | 26.21 Bn | 358.27 Mn | 94.83% |
| 10 | Incyte | 25.53 Bn | 21.00 Bn | 1.57 Bn | 44.59% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.59% |
| Mar 31, 2026 | 91.73% |
| Dec 31, 2025 | 48.74% |
| Sep 30, 2025 | 298.45% |
| Jun 30, 2025 | 191.09% |
| Mar 31, 2025 | -6.69% |
| Dec 31, 2024 | 0.07% |
| Sep 30, 2024 | -37.84% |
| Jun 30, 2024 | -318.43% |
| Mar 31, 2024 | 681.22% |
| Dec 31, 2023 | 606.51% |
| Sep 30, 2023 | 51.87% |
| Jun 30, 2023 | 26.09% |
| Mar 31, 2023 | -42.87% |
| Dec 31, 2022 | -94.95% |
| Sep 30, 2022 | -37.95% |
| Jun 30, 2022 | 8.01% |
| Mar 31, 2022 | -29.03% |
| Dec 31, 2021 | 276.28% |
| Sep 30, 2021 | 1,295.42% |